Stockreport

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]

Immunic, Inc.  (IMUX) 
PDF – Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 – – Raised Proceeds of $200 Million in a [Read more]